IRCT20210906052395N1
Completed
Phase 3
Assessment of Empagliflozin effect on renal outcome in patients with type 2 diabetes mellitus
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- ephropathy and proteinuria in diabetic nephropathy patients taking empagliflozin.
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Enrollment
- 96
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient with type2 diabetes
- •over the age of 18 years
- •GFR\<60 or albuminuria
Exclusion Criteria
- •Recent myocatdial infarction and PCI
- •Dialysis in the last ninety days
- •Renal failure for reasons other than diabetes
- •Recurrent urinary tract infections
- •History of amputation due to diabetes
- •Bladder cancer
- •Active diabetic foot ulcer
- •type 1 diabetes
- •Pregnancy and lactation
- •Major surgery performed in the last 28 days
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 4
Effect of empagliflozin on renal events in non-diabetic chronic kidney disease patientsChronic kidney disease.Chronic kidney disease (CKD)IRCT20211104052965N1Shahid Beheshti University of Medical Sciences458
Active, not recruiting
Phase 1
Effect of treatment with Empagliflozin alone or in combination with Semaglutide on protein in the urine in persons with type 2 diabetes and elevated urinary protein.Type 2 diabetes with renal complicationsMedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2019-003175-19-DKSteno Diabetes Center Copenhagen80
Active, not recruiting
Phase 1
Effects of empagliflozin on urine output and renal function in patients with acute heart failureacute decompensated heart failureMedDRA version: 20.0Level: LLTClassification code 10000803Term: Acute heart failureSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2018-003692-35-DEFriedrich Schiller University Jena60
Unknown
Phase 4
Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and AlbuminuriaType 2 Diabetes With Renal ManifestationsNCT04061200Steno Diabetes Center Copenhagen80
Recruiting
Phase 2
Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis PatientsEnd Stage Renal Disease on DialysisPeritoneal Dialysis ComplicationSodium-glucose Cotransporter-2 InhibitorResidual Kidney FunctionNCT06483074Chinese University of Hong Kong48